Novo Nordisk A/S with ticker code (NVO) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 171.97 and 118.6 with a mean TP of 150.56. With the stocks previous close at 141.46 this would imply there is a potential upside of 6.4%. The 50 day moving average now sits at 139.24 and the 200 day MA is 118.14. The market cap for the company is $319,671m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $340,235m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
